Y
Yuanqi Biotechnology
Intelligent and industrialized cell bank network
About Yuanqi Biotechnology
Yuanqi Biotechnology, officially known as OriginCell Technology Group, was co-founded in July 2014 by the accomplished entrepreneur Qu Jianguo and the publicly traded company Canature Health (300272). The venture was initiated with a significant first-round investment of 1.5 billion RMB. Qu Jianguo serves as the company's chairman and chief engineer, bringing a wealth of experience from his previous successes. Before delving into the health industry, he founded Shenhua Industrial, one of the first eight companies listed on the Shanghai Stock Exchange, and later established Canature Health, the first publicly-listed home water treatment company in China. This entrepreneurial journey reflects a consistent focus on innovation and market foresight, which he now applies to the life sciences sector.
OriginCell operates within the biotechnology and life sciences markets, focusing on cell technology. The group's core business is the creation of a standardized and intelligent network of cell banks. Its operations are comprehensive, spanning third-party cell storage, the development and manufacturing of automated cryogenic storage equipment for biological samples, immunotherapy drug development, and cell preparation services. The company serves a range of clients, including hospitals and research institutions, providing them with advanced solutions for biological sample cryopreservation. Its business model is diversified across this ecosystem, generating revenue through services and the sale of specialized equipment.
The company's key offerings include automated, intelligent, deep-cryogenic biological sample storage equipment, designed to address the challenges of traditional manual storage. One of its flagship developments is an unmanned 5G-enabled fully automated cell bank. Its subsidiary, Shanghai Origincell Biological Cryo Equipment Co., Ltd., produces a range of products including the BSN Honeycomb-style automated deep-low temperature bio-sample storage equipment (-196°C). These systems aim to ensure sample safety and quality by preventing cross-contamination and avoiding repeated freeze-thaw cycles through patented technologies like a honeycomb storage structure and single-tube picking mechanisms. The company has built a substantial intellectual property portfolio, with hundreds of patents filed and granted domestically and internationally.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Feb 2023 | $45M | $900M | Qatar Investment Authority · Xiamen C&D · RTW Investments · Qiming Venture Partners | ↗ |
Growth signals
Latest recorded traffic for Yuanqi Biotechnology is 130 monthly website visits, down 58.1% over the last three months. Yuanqi Biotechnology's team grew 6.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Yuanqi Biotechnology in its local ecosystem
The Yuanqi Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Qatar Investment Authority
Xiamen C&D
RTW Investments
Qiming Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Yuanqi Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Yuanqi Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








